Nirmal Kilambi, MD
Urology · Fayetteville, ARNPI 1861476897
Payments from drug & device makers
What this record shows
The money is spread across several categories — ownership interests (51.9%), food and beverage and education — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Ozark Cryosurgery, LLC at 51.9% of the total. Reporting peaked in 2020 at $9,807 and has fallen 82.7% since, to $1,692 in 2025.
Across 227 payments — averaging $155.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ozark Cryosurgery, LLC$18K
- Medtronic$7K
- Intuitive Surgical$6K
- Boston Scientific$2K
- Coloplast$488
- Sumitomo Pharma America, Inc.$308
- plus $2K from 32 others
What the payments were for
- Travel & lodging$4,44113%
- Food & beverage$6,46018%
- Education$6,10017%
- Ownership interest$18,31252%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ozark Cryosurgery, LLC | 3 | $18,312 |
| Medtronic | 77 | $6,547 |
| Intuitive Surgical | 2 | $6,000 |
| Boston Scientific | 34 | $1,641 |
| Coloplast | 22 | $488 |
| Sumitomo Pharma America, Inc. | 15 | $308 |
| Axonics, Inc. | 6 | $180 |
| Agiliti Health, Inc. | 4 | $153 |
| Procept Biorobotics Corporation | 3 | $149 |
| Pfizer | 7 | $121 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $120 |
| Astellas Pharma US Inc | 2 | $116 |
| AstraZeneca | 1 | $116 |
| Myovant Sciences Inc. | 6 | $112 |
| Myriad Genetic Laboratories, Inc. | 6 | $97 |
| Healthtronics Stone Solutions, LLC | 2 | $86 |
| Urogen Pharma, Inc. | 3 | $65 |
| Momentis Surgical Inc. | 1 | $65 |
| AbbVie | 3 | $60 |
| Blue Earth Diagnostics | 3 | $60 |
| Accord Healthcare, Inc. | 3 | $47 |
| Ferring Pharmaceuticals Inc. | 2 | $45 |
| Olympus America Inc. | 2 | $45 |
| Teleflex LLC | 1 | $43 |
| Verity Pharmaceuticals Inc. | 2 | $40 |
| Urovant Sciences Inc | 2 | $34 |
| Antares Pharma, Inc. | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Vertex | 1 | $26 |
| Innovation Technologies Inc | 1 | $26 |
| Merck | 1 | $23 |
| Progenics Pharmaceuticals, Inc. | 1 | $22 |
| Tolmar, Inc. | 1 | $20 |
| Conmed Corporation | 1 | $19 |
| Civco Medical Instruments | 1 | $18 |
| Laborie Medical Technologies Corp. | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Cook Medical LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,000
- INTERSTIM$3,725
- ALTAVIVA$734
- GREENLIGHT$264
- NURTEC ODT$120
- Advantage System$117
- ULTOMIRIS$116
- LithoVue$113
- Luja Coude$111
- REZUM$106
- UPSYLON$106
- Axonics r-SNM System$104
How this compares
$35,314 in reported general payments places this provider in the 85th percentile of 88 urology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 41 | $28,159 |
| Solifenacin Succinate | 170 | $5,375 |
| Desmopressin Acetate | 16 | $1,333 |
| Bicalutamide | 50 | $1,131 |
| Tamsulosin Hcl | 79 | $758 |
| Finasteride | 105 | $638 |
| Oxybutynin Chloride ErOxybutynin Chloride | 26 | $429 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 56 | $298 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $131 |
| Tramadol Hcl | 18 | $48 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $34 |
| Alprazolam | 17 | $10 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $116 | $28,15941 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 88 urology providers in Arkansas.
Other urology in Fayetteville
- Charles JacksonFayetteville$9K
- Robert GrandFayetteville$6K
- Richard McWhorterFayetteville$4K
- Michael WilsonFayetteville$2K
- Donald MooneyLittle Rock$148K
- Timothy GoodsonLittle Rock$147K
- Ronald KuhnNorth Little Rock$138K
- Caleb BozemanLittle Rock$136K
- David CoussensLittle Rock$134K
- Timothy LangfordLittle Rock$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.